TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Collection of clinical events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Systematized vascular ultrasound explorations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: absence of allergic reaction
Endpoint domain: Adverse events/effects
Primary endpoint: safety of PulmoBind
Endpoint domain: Adverse events/effects
Primary endpoint: detection of abnormal pulmonary circulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change in temperature over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: thermal map of tissue volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients classified as COVID-19 positive
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Feasibility of lung density map extraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Abnormal Chemistry Laboratory Toxicity Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Abnormal Hematology Laboratory Toxicity Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Unsolicited Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Tinnitus annoyance Visual Analogue Score (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Body Dissatisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain-free Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central Endothelial Cell Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daunorubicin Hydrochloride Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daunorubicin Hydrochloride Volume of Distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression Level of IGFBP-3 Gene
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Soft tissue infections
Endpoint domain: Adverse events/effects
Primary endpoint: Pulmonary concentration of inflammation mediators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Readmission due to heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Post-discharge Utilization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of Pharmacists Who Objected to Participate in Dispensing Mifeprex
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Pharmacists Who Report Being Satisfied With Pharmacy Dispensing of Mifeprex
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Length of hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Intensive Care Unit (ICU) hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: General Health Status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of pain crises
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of responders to capsaicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in miRNA and EV content in blood samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Non-accident mortality or admission
Endpoint domain: Mortality/survival
Primary endpoint: Performance over BCI sessions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Halitosis Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Vaccinated Participants Who Experienced Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: New and ongoing adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: LTBI diagnosis after travel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Response rate of CD19 and CD22 CAR-T treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New or worsening symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amyloid-beta Concentration in CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in psychological stress
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: rate of in-stent restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline Cortisol (Saliva Sampling) at 6 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change from baseline subscales of mood survey scale at 6 hours
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Tuberculosis-immune Reconstitution Inflammatory Syndrome Events
Endpoint domain: Adverse events/effects
Primary endpoint: Recovery of Myocardial Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical pain response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ASHA Shift Ear (Left)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ASHA Shift Ear (Right)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ASHA Shift Ear (Either)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ASHA Shift Ear (Both)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ASHA Shift Ear (Trigger Hand)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ASHA Shift Ear (Non-Trigger Hand)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average worst pain score with movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Conduction Amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Increases in Conduction Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in Latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Baseline Fugl-Meyer Assessment of Motor Recovery (Upper Extremity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of endoscopic vertical gastroplasty + lifestyle modification
Endpoint domain: Adverse events/effects
Primary endpoint: Histological improvement of fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Quitting success rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: food consumption-induced neural activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Viscoelasticity of the contracted Tibialis anterior muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Efficiency of ocular protection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean AUCins.0-12h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence rate of ventilator induced diaphragm dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Serum concentration of tranexamic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Zarit Burden Inventory
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Digit Span Forward from the Wechsler Adult Intelligence Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Digit Span Backward from the Wechsler Adult Intelligence Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Letters and Numbers from the Wechsler Adult Intelligence Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Spanish phonemic fluency test (PMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Endotoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Soluble CD14 (sCD14)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: percentage change in pSTAT3 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with abnormal thyroid function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Sit up test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lateral bridge tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biering-Sorenson Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isokinetic Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cardiac PCr/ATP ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Thymic thoracic ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of Mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of tissue oxygen saturation (StO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of lesions assessed by IGA scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in buccal soft tissue profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of foot infection
Endpoint domain: Adverse events/effects
Primary endpoint: Readmission for foot ulcer
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Attack rate of early-onset GBS disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Maximum observed Plasma concentration (Cmax) for cabotegravir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of maximum observed plasma concentration (Tmax) for cabotegravir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration - time curve from time zero to last quantifiable time point (AUC[0-t]) for cabotegravir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects With Index Event Safety Outcomes
Endpoint domain: Mortality/survival
Primary endpoint: Immunological recall response to tetanus vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean fluorescence measurement for carious lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RI Events (Oxygen Saturation < 90%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: RI Events (Apneas/Hypopneas > 15 Sec Duration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants That Experienced at Least One Study-Related Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Time in Target Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-Efficacy for Exercise
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sleep evaluation
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Postoperative complications (MCDC grade 2 and higher)
Endpoint domain: Adverse events/effects
Primary endpoint: Confirmed clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants requiring one or more mask re-fits
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with drug related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in minimum erythema dose (MED)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of subjects with drug related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses at Day 169
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses at Day 253
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Disease Perception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cardio-Respiratory Fitness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment outcomes of ACS patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma tryptophan level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of tryptophan metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SCQOLIT questionnaire response rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PCR adjusted adequate clinical and parasitological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of thyroid function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Patient-reported Tinnitus loudness on a Numerical Rating Scale (TLQ NRS loudest)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Lesion Metabolic Avidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cervical and ocular vestibular-evoked myogenic potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of NRL972
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of recording time spent with cuff overinflation or underinflation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence, duration and intensity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in study test results from baseline values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: True number of ALK positives and negatives
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentages of Subjects Achieving Hemagglutination Inhibition (HI) Titers ≥40
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Phantom limb pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breath carbon dioxide production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Vitamin C level after administration of study drug
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients pursuing effective osteoporosis treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of Technical Success at One-Month Post-Index Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Safety and Effectiveness Indicators at One-Year Post-Index Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Taste alteration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of confirmed responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Levels of phytochemicals and their in vivo metabolites in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Difference in administered anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Participants With Grade 3 Hand-Foot Syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Overall improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAI Antibody Responses for Vaccine Homologous Influenza Strains Expressed as Ratio of Geometric Mean Fold Ratio (GMFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Difference in the Seroconversion Rate (SCR) HAI Antibody Responses for Vaccine Homologous Influenza Strains Expressed as a Percentage of Participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects With Solicited Local and Systemic Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: hospital day
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of patients with anastomotic leakage
Endpoint domain: Adverse events/effects
Primary endpoint: Protein-specific Antigen (PSA) Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to Re-Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Removal of dental plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood sample results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiology testing/cardiac autonomic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: UPDRS-IV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Columbia Suicide Rating
Endpoint domain: Adverse events/effects
Primary endpoint: Total number of phlebotomies
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reproductive Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Radiologic Diagnosis of nonalcoholic steatohepatitis (NASH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Plasma quercetin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Neuropsychological Test Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of injury to blood vessel
Endpoint domain: Adverse events/effects
Primary endpoint: Time spent in the normal range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Red Fluorescent Cells in Sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in histological Grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in serum FGF 21
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Volume of Fluid Administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postprandial glycaemia (2h plasma glucose level)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Gain in crown length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Change in alveolar bone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Frequency of early-morning, day- and night-time COPD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Subjects Exhibiting Anti-motavizumab Antibodies
Endpoint domain: Adverse events/effects
Primary endpoint: Balance of fat in feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in fasting lipoprotein profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sensitivity at AHI threshold value of 5/h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity at AHI threshold value of 15/h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity at AHI threshold value of 30/h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity at AHI threshold value of 5/h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity at AHI threshold value of 15/h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity at AHI threshold value of 30/h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume change of skin lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: late toxicity of radiation therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Hematologic Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Average number of Raynaud's phenomenon attacks per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of pesticide exposures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Grade 3 or 4 Hematological or Liver Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) in Infections and Infestations
Endpoint domain: Adverse events/effects